title: Development of amyloidosis in patients with rheumatoid arthritis under TNF-blocking agents.
authors.forename: Raquel
authors.initials: R
authors.lastname: Roque
authors.forename: Sofia
authors.initials: S
authors.lastname: Ramiro
authors.forename: Ana
authors.initials: A
authors.lastname: Cordeiro
authors.forename: Pedro
authors.initials: P
authors.lastname: Gonçalves
authors.forename: Silva
authors.initials: S
authors.lastname: Da Canas
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Santos
mesh_terms: D000368:Aged; D000686:Amyloidosis / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001799:Blood Sedimentation; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D000685:Serum Amyloid A Protein / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000685:Serum Amyloid A Protein; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept